Trial Profile
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ANCHOR-CRC
- Sponsors Pierre Fabre
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 16 Jul 2023 This trial has been completed in Netherlands (Global end date: 27 Apr 2023).
- 08 Jul 2023 This trial has been completed in France (Global end date: 27 Apr 2023).